Bart J. Biemond

7.8k total citations · 2 hit papers
126 papers, 3.7k citations indexed

About

Bart J. Biemond is a scholar working on Genetics, Hematology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Bart J. Biemond has authored 126 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Genetics, 72 papers in Hematology and 20 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Bart J. Biemond's work include Hemoglobinopathies and Related Disorders (71 papers), Iron Metabolism and Disorders (20 papers) and Blood groups and transfusion (17 papers). Bart J. Biemond is often cited by papers focused on Hemoglobinopathies and Related Disorders (71 papers), Iron Metabolism and Disorders (20 papers) and Blood groups and transfusion (17 papers). Bart J. Biemond collaborates with scholars based in Netherlands, United States and Switzerland. Bart J. Biemond's co-authors include Erfan Nur, Marcel Levi, Gert J. Ossenkoppele, Bob Löwenberg, Johan Maertens, Thomas Pabst, Edo Vellenga, John‐John B. Schnog, Dees P. M. Brandjes and Carlos Graux and has published in prestigious journals such as New England Journal of Medicine, Circulation and Journal of Clinical Investigation.

In The Last Decade

Bart J. Biemond

119 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia

2009 596 citations Bob Löwenberg, Gert J. Ossenkoppele et al. profile →
Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome

2022 159 citations Tim Grob, Adil S. A. Al Hinai et al. Blood profile →

Peers

Countries citing papers authored by Bart J. Biemond

Since Specialization

Citations

This map shows the geographic impact of Bart J. Biemond's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bart J. Biemond with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bart J. Biemond more than expected).

Fields of papers citing papers by Bart J. Biemond

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bart J. Biemond. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bart J. Biemond. The network helps show where Bart J. Biemond may publish in the future.

Co-authorship network of co-authors of Bart J. Biemond

This figure shows the co-authorship network connecting the top 25 collaborators of Bart J. Biemond. A scholar is included among the top collaborators of Bart J. Biemond based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bart J. Biemond. Bart J. Biemond is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The role of red blood cell characteristics and viscosity in sickle cell retinopathy and maculopathy 2025 ·British Journal of Haematology ·(unknown), Roselie M.H. Diederen, Ingeborg Klaassen, (unknown), (unknown), Rob van Zwieten, Reinier O. Schlingemann, Erfan Nur, Bart J. Biemond	0
2	Effect of allogeneic hematopoietic stem cell transplantation on sickle cell disease‐related organ complications: A systematic review and meta‐analysis 2024 ·American Journal of Hematology ·(unknown), (unknown), Michael R. DeBaun, (unknown), Bart J. Biemond, Erfan Nur	5
3	Neutrophils in sickle cell disease: Exploring their potential role as a therapeutic target 2024 ·American Journal of Hematology ·(unknown), (unknown), Bart J. Biemond, Karin Fijnvandraat, Robin van Bruggen, Erfan Nur	4
4	Azathioprine/hydroxyurea preconditioning prior to nonmyeloablative matched sibling donor hematopoietic stem cell transplantation in adults with sickle cell disease: A prospective observational cohort study 2024 ·American Journal of Hematology ·(unknown), (unknown), Mette D. Hazenberg, Man Tang, (unknown), (unknown), Charlotte F.J. Van Tuijn, Jean‐Louis Kerkhoffs, Caroline E. Rutten, Sacha Zeerleder, Josu de la Fuente, Bart J. Biemond, Erfan Nur	1
5	Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi‐state modeling 2024 ·Cancer Medicine ·(unknown), Yvette van Norden, Jurjen Versluis, Anita W. Rijneveld, Bronno van der Holt, Okke de Weerdt, Bart J. Biemond, Arjan A. van de Loosdrecht, (unknown), Mar Bellido, Michel van Gelder, Walter J. F. M. van der Velden, Dominik Selleslag, (unknown), Vincent H. J. van der Velden, Liesbeth C. de Wreede, Douwe Postmus, Francesco Pignatti, Jan J. Cornelissen	2
6	ATG versus PTCy in matched unrelated donor haematopoietic stem cell transplantations with non‐myeloablative conditioning 2023 ·British Journal of Haematology ·(unknown), David C. de Leeuw, Caroline E. Rutten, Otto Visser, Man Tang, (unknown), (unknown), Bart J. Biemond, Arjan A. van de Loosdrecht, Mette D. Hazenberg, Ellen Meijer, Erfan Nur	2
7	One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study 2023 ·Blood Advances ·(unknown), Minke A.E. Rab, Brigitte A. van Oirschot, (unknown), (unknown), Anita W. Rijneveld, Marjon H. Cnossen, Erfan Nur, Bart J. Biemond, Marije Bartels, Judith Jans, Wouter W. van Solinge, Roger E. G. Schutgens, Richard van Wijk, Eduard J. van Beers	8
8	Natural history and rate of progression of retinopathy in adult patients with sickle cell disease: an 11-year follow-up study 2023 ·Blood Advances ·(unknown), Roselie M.H. Diederen, (unknown), Erfan Nur, Reinier O. Schlingemann, Bart J. Biemond	10
9	Feasibility of CD19 CAR T-cell therapy in patients with cardiac lymphoma 2023 ·Leukemia & lymphoma ·Maria T. Kuipers, Anne M. Spanjaart, Francesca Bonifazi, (unknown), Pier Luigi Zinzani, Catherine Thiéblemont, Mathilde Baudet, Bart J. Biemond, Wouter E.M. Kok, Marie José Kersten	0
10	Case report: Successful treatment with daratumumab for pure red cell aplasia in a patient with mixed lymphoid chimerism after ABO-mismatched stem cell transplant for sickle cell disease 2023 ·Frontiers in Immunology ·(unknown), Bart J. Biemond, Erfan Nur	4
11	Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome breakdown → 2022 ·Blood ·Tim Grob, Adil S. A. Al Hinai, Mathijs A. Sanders, François G. Kavelaars, Melissa Rijken, Patrycja Gradowska, Bart J. Biemond, Dimitri Breems, Johan Maertens, Marinus van Marwijk Kooy, Thomas Pabst, Okke de Weerdt, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht, Gerwin Huls, Jan J. Cornelissen, H. Berna Beverloo, Bob Löwenberg, Mojca Jongen‐Lavrencic, Peter J.M. Valk	159
12	Higher Prevalence of Autoimmune Diseases in Patients with Sickle Cell Disease 2021 ·Blood ·Man Tang, Erfan Nur, Charlotte F.J. Van Tuijn, Bart J. Biemond	4
13	Haploidentical Allogeneic Stem Cell Transplantation in Sickle Cell Disease: A Systematic Review and Meta-Analysis 2021 ·Transplantation and Cellular Therapy ·(unknown), (unknown), Mariska Leeflang, Josu de la Fuente, Adetola A. Kassim, Bart J. Biemond, Erfan Nur	22
14	Vaso‐occlusive crisis and acute chest syndrome in sickle cell disease due to 2019 novel coronavirus disease (COVID‐19) 2020 ·American Journal of Hematology ·Erfan Nur, (unknown), Charlotte F.J. Van Tuijn, Man Tang, Bart J. Biemond	61
15	Identification of genetic biomarkers for alloimmunization in sickle cell disease 2019 ·British Journal of Haematology ·Sanne M. Meinderts, (unknown), (unknown), Martin de Boer, Karin van Leeuwen, Bart J. Biemond, Anita W. Rijneveld, Jean‐Louis Kerkhoffs, Anoosha Habibi, Robin van Bruggen, Taco W. Kuijpers, C. Ellen van der Schoot, France Pirenne, Karin Fijnvandraat, Michael W.T. Tanck, Timo K. van den Berg	16
16	Randomized Maintenance Therapy with Azacitidine (Vidaza) in Older Patients (>= 60 years of age) with Acute Myeloid Leukemia (AML) and Refractory Anemia with Excess of Blasts (RAEB, RAEB-t). Results of the HOVON97 Phase III Randomized Multicentre Study (EudraCT 2008-001290-15) 2017 ·Blood ·(unknown), Dana Chiţu, Violaine Havelange, Mojca Jongen‐Lavrencic, (unknown), Bart J. Biemond, (unknown), (unknown), Carlos Graux, (unknown), Okke de Weerdt, Dimitri Breems, Saskia K. Klein, Jürgen Kuball, Gert J. Ossenkoppele, Bob Löwenberg, Edo Vellenga	5
17	Sevuparin : effects on hemostasis of a novel polysaccharide drug derived from heparin 2015 ·Journal of Thrombosis and Haemostasis ·Maria Lindgren, (unknown), Bart J. Biemond, Sofia Ramström, Tomas Lindahl, (unknown), (unknown), Marie Wahlgren, John Hogwood, Elaine Gray, E. Holmer	2
18	Increased efflux of oxidized glutathione (GSSG) causes glutathione depletion and potentially diminishes antioxidant defense in sickle erythrocytes 2011 ·Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease ·Erfan Nur, (unknown), Dirk R. de Waart, John‐John B. Schnog, Hans‐Martin Otten, Dees P. M. Brandjes, Bart J. Biemond, Ronald P.J. Oude Elferink	38
19	Intracoronary infusion of mononuclear cells potentially prevents post-infarct ventricular remodeling in patients with an initial dilated left ventricle: a HEBE substudy 2009 ·European Heart Journal ·Anja M. van der Laan, Pieter A. van der Vleuten, Alexander Hirsch, Robin Nijveldt, Willem J. van der Giessen, Bart J. Biemond, Jan G.P. Tijssen, Albert C. van Rossum, F. Zijlstra, Jan J. Piek, (unknown)	1
20	Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor. 1998 ·Journal of Clinical Investigation ·Monique C. Minnema, Philip W. Friederich, Marcel Levi, Peter A. von dem Borne, Laurent O. Mosnier, Joost C.M. Meijers, Bart J. Biemond, C. Erik Hack, Bonno N. Bouma, Hugo Ten Cate	159

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact